Recommendations
This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.
Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.
Definitions and criteria for the categorisation of medicines
Legacy Merseyside
New Cheshire and Merseyside
Transition of Commissioning Policies
On 1st July 2022 NHS Cheshire and Merseyside Integrated Care Board (ICB) became the new statutory body responsible for ensuring health care services are available to meet the reasonable needs of the people of Cheshire & Merseyside.
Until such time as a single suite of commissioning policies can be developed and adopted, NHS Cheshire and Merseyside will continue to adopt and operate the CCG policies it has inherited at Place/borough level, which means that there will be no immediate change in commissioning policy for local people resident in those Places/boroughs from what was in place prior to 1st July 2022.
Documents
The Pan Mersey Area Prescribing Committee recommends the prescribing of CANAGLIFLOZIN, DAPAGLIFLOZIN, EMPAGLIFLOZIN and ERTUGLIFLOZIN as COMBINATION THERAPIES as options for treating type 2 diabetes in adults in accordance with NICE guidance.
The Pan Mersey Area Prescribing Committee recommends the prescribing ofCANAGLIFLOZIN, DAPAGLIFLOZIN, EMPAGLIFLOZIN and ERTUGLIFLOZIN as
MONOTHERAPIES as options for treating type 2 diabetes in adults in accordance with NICE TA390 and TA572.
The Pan Mersey Area Prescribing Committee recommends the prescribing ofCANAGLIFLOZIN, DAPAGLIFLOZIN, EMPAGLIFLOZIN and ERTUGLIFLOZIN as
MONOTHERAPIES as options for treating type 2 diabetes in adults in accordance with NICE TA390 and TA572.
The Pan Mersey Area Prescribing Committee recommends the prescribing of CANAGLIFLOZIN, DAPAGLIFLOZIN, EMPAGLIFLOZIN and ERTUGLIFLOZIN as COMBINATION THERAPIES as options for treating type 2 diabetes in adults in accordance with NICE guidance.
The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of DENOSUMAB solution for injection (Prolia®) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy.
The Pan Mersey Area Prescribing Committee recommends the prescribing ofCANAGLIFLOZIN, DAPAGLIFLOZIN, EMPAGLIFLOZIN and ERTUGLIFLOZIN as
MONOTHERAPIES as options for treating type 2 diabetes in adults in accordance with NICE TA390 and TA572.
The Pan Mersey Area Prescribing Committee recommends the prescribing of CANAGLIFLOZIN, DAPAGLIFLOZIN, EMPAGLIFLOZIN and ERTUGLIFLOZIN as COMBINATION THERAPIES as options for treating type 2 diabetes in adults in accordance with NICE guidance.
The Pan Mersey Area Prescribing Committee recommends the prescribing of CANAGLIFLOZIN, DAPAGLIFLOZIN, EMPAGLIFLOZIN and ERTUGLIFLOZIN as COMBINATION THERAPIES as options for treating type 2 diabetes in adults in accordance with NICE guidance.
The Pan Mersey Area Prescribing Committee recommends the prescribing ofCANAGLIFLOZIN, DAPAGLIFLOZIN, EMPAGLIFLOZIN and ERTUGLIFLOZIN as
MONOTHERAPIES as options for treating type 2 diabetes in adults in accordance with NICE TA390 and TA572.
The Pan Mersey Area Prescribing Committee recommends the prescribing of FreeStyle Optium® blood glucose and FreeStyle Optium® ß-ketone test strips only for use with FreeStyle Libre® specifically in patients who are using carbohydrate counting/ bolus advice.
The Pan Mersey Area Prescribing Committee recommends the prescribing of GLP-1 mimetics in combination with insulin for type 2 diabetes, only with specialist care advice and ongoing support from a consultant-led MDT.
The Cheshire and Merseyside Area Prescribing Group recommends the use of hybrid closed loop systems for managing blood glucose levels in type 1 diabetes, by specialists only, in accordance with NICE TA943.
NHS Cheshire and Merseyside APPROVED
The Pan Mersey Area Prescribing Committee recommends the prescribing of INSULIN DEGLUDEC 100units/mL and 200 units/mL solution for subcutaneous injection (Tresiba®), initiated by specialists only, for type 1 and type 2 diabetes for specific patient groups, taking into account NICE guidance
The Pan Mersey Area Prescribing Committee does not recommend the prescribing of CONJUGATED OESTROGENS and BAZEDOXIFENE 0.45mg/20mg modified release tablets (Duavive®) for the treatment of oestrogen deficiency in postmenopausal women with a uterus.
The Pan Mersey Area Prescribing Committee recommends the prescribing of RELUGOLIX-ESTRADIOL-NORETHISTERONE ACETATE tablets (Ryeqo®▼) for treating uterine fibroids in accordance with NICE TA832.
NHS Cheshire and Merseyside APPROVED
The Pan Mersey Area Prescribing Committee recommends the prescribing of ROMOSOZUMAB solution for injection (EVENITY®▼), by specialists only, for treating severe osteoporosis in accordance with NICE TA791.
NHS Cheshire and Merseyside APPROVED
The Cheshire and Merseyside Area Prescribing Group recommends the prescribing of SEMAGLUTIDE injection (Wegovy®▼), by specialists only, for managing overweight and obesity within a specialist weight management service, in accordance with NICE TA875.
NHS Cheshire and Merseyside APPROVED
The Cheshire and Merseyside Interim Area Prescribing Group recommends the prescribing of SOMATROGON injection (Ngenla®▼), by specialists only, for treating growth disturbance in children and young people aged 3 years and over, in accordance with NICE TA863.
NHS Cheshire and Merseyside APPROVED